FDA Accepts Blueprints NDA for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and FourthLine GIST

FDA Accepts Blueprint’s NDA for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

CAMBRIDGE, Mass., Aug. 7, 2019 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avapritinib for the treatment of adult patients with PDGFRA Exon …

More From BioPortfolio on "FDA Accepts Blueprint’s NDA for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST"